Kristen Kluska

Stock Analyst at Cantor Fitzgerald

(4.28)
# 432
Out of 4,981 analysts
239
Total ratings
42.53%
Success rate
21.03%
Average return

Stocks Rated by Kristen Kluska

Ultragenyx Pharmaceutical
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $30.31
Upside: +246.42%
PTC Therapeutics
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $61.11
Upside: +93.09%
Monopar Therapeutics
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $49.48
Upside: +49.56%
Supernus Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $42$46
Current: $45.47
Upside: +1.17%
Rigel Pharmaceuticals
Aug 6, 2025
Maintains: Neutral
Price Target: $23$32
Current: $37.96
Upside: -15.70%
Eupraxia Pharmaceuticals
Jul 24, 2025
Initiates: Overweight
Price Target: $11
Current: $5.40
Upside: +103.70%
Zevra Therapeutics
Jul 10, 2025
Maintains: Overweight
Price Target: $25$29
Current: $7.75
Upside: +274.19%
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $5.39
Upside: +196.85%
Fulcrum Therapeutics
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $7.02
Upside: +42.45%
Capricor Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $6.36
Upside: +371.70%
Maintains: Overweight
Price Target: $163$81
Current: $17.39
Upside: +365.78%
Reiterates: Overweight
Price Target: $7
Current: $3.07
Upside: +128.01%
Maintains: Overweight
Price Target: $67$123
Current: $53.62
Upside: +129.39%
Reiterates: Overweight
Price Target: $90
Current: $3.26
Upside: +2,660.74%
Reiterates: Overweight
Price Target: $7
Current: $1.85
Upside: +278.38%
Maintains: Overweight
Price Target: $99$132
Current: $59.80
Upside: +120.74%
Reiterates: Overweight
Price Target: $25
Current: $16.11
Upside: +55.18%
Reiterates: Overweight
Price Target: $67
Current: $24.44
Upside: +174.20%
Reiterates: Overweight
Price Target: $21
Current: $7.99
Upside: +162.83%
Reiterates: Overweight
Price Target: $29
Current: $8.07
Upside: +259.36%
Initiates: Overweight
Price Target: $17
Current: $5.05
Upside: +236.63%
Initiates: Overweight
Price Target: $8
Current: $2.84
Upside: +181.69%
Maintains: Overweight
Price Target: $28$58
Current: $16.49
Upside: +251.84%
Reiterates: Overweight
Price Target: $11
Current: $2.43
Upside: +352.67%
Reiterates: Overweight
Price Target: $18
Current: $6.43
Upside: +179.94%
Reiterates: Overweight
Price Target: $14
Current: $4.25
Upside: +229.41%
Reiterates: Overweight
Price Target: $13
Current: $1.47
Upside: +784.35%
Reiterates: Overweight
Price Target: $21
Current: $1.63
Upside: +1,188.34%
Reiterates: Overweight
Price Target: $6
Current: $1.34
Upside: +347.76%
Downgrades: Neutral
Price Target: $90$20
Current: $1.04
Upside: +1,823.08%
Reiterates: Overweight
Price Target: $23
Current: $3.82
Upside: +502.09%
Reiterates: Overweight
Price Target: $900
Current: $1.58
Upside: +56,862.03%
Initiates: Overweight
Price Target: $400
Current: $2.87
Upside: +13,837.28%
Downgrades: Neutral
Price Target: $1,250$85
Current: $0.93
Upside: +9,005.52%
Initiates: Overweight
Price Target: $180
Current: $6.93
Upside: +2,497.40%
Initiates: Overweight
Price Target: $180
Current: $3.01
Upside: +5,880.07%
Downgrades: Neutral
Price Target: $15$11
Current: $1.07
Upside: +928.04%
Initiates: Overweight
Price Target: $60
Current: $0.95
Upside: +6,185.36%
Initiates: Overweight
Price Target: $90
Current: $1.26
Upside: +7,042.86%
Assumes: Overweight
Price Target: $10,620$2,520
Current: $1.51
Upside: +166,787.42%
Initiates: Overweight
Price Target: $160
Current: $0.47
Upside: +33,605.50%